{"id":"NCT01174160","sponsor":"Advanz Pharma","briefTitle":"A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)","officialTitle":"A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2012-09","completion":"2012-10","firstPosted":"2010-08-03","resultsPosted":"2015-12-15","lastUpdate":"2015-12-15"},"enrollment":123,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atrial Fibrillation"],"interventions":[{"type":"DRUG","name":"vernakalant hydrochloride","otherNames":["MK-6621"]},{"type":"DRUG","name":"Placebo to vernakalent hydrochloride","otherNames":["Saline"]}],"arms":[{"label":"vernakalant HCl","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will investigate if treatment with vernakalant hydrochloride (MK-6621) results in a greater proportion of patients with treatment-induced conversion of Atrial Fibrillation to sinus rhythm compared to placebo.","primaryOutcome":{"measure":"Proportion of Patients With Treatment-induced Conversion of Atrial Fibrillation to Sinus Rhythm","timeFrame":"Within 90 minutes after first exposure","effectByArm":[{"arm":"Vernakalant IV","deltaMin":29,"sd":null},{"arm":"Placebo","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":17},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":55},"commonTop":["Bradycardia","Ventricular tachycardia","Sneezing","Hypokalaemia","Dizziness"]}}